Cargando…

Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement

BACKGROUND: Olmesartan medoxomil (OLM), an anti-hypertensive agent administered orally has absolute bioavailability of only 26% due to the poor aqueous solubility (<7.75 μg/ml). The present investigation aimed at enhancing the oral bioavailability of OLM by improving its solubility and dissolutio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakkar, Hetal Paresh, Patel, Bindesh Vishnubhai, Thakkar, Sneha Piyush
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications Pvt Ltd 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178951/ https://www.ncbi.nlm.nih.gov/pubmed/21966165 http://dx.doi.org/10.4103/0975-7406.84459

Ejemplares similares

Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology
por: Attari, Zenab, et al.
Publicado: (2016)

Preparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability Improvement
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene
por: Patel, B. Divyakant, et al.
Publicado: (2012)

Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

Olmesartan medoxomil for the treatment of hypertension in children and adolescents
por: Tocci, Giuliano, et al.
Publicado: (2011)

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
por: Greathouse, Mark
Publicado: (2006)

Spectrophotometric Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in Tablet
por: Rote, A. R., et al.
Publicado: (2010)

Olmesartan medoxomil: Allergic reaction: case report
Publicado: (2022)

Olmesartan medoxomil: current status of its use in monotherapy
por: Brunner, Hans R
Publicado: (2006)

Small bowel enteropathy associated with olmesartan medoxomil treatment
por: Galanopoulos, Michail, et al.
Publicado: (2017)

Olmesartan-medoxomil: Sprue-like enteropathy: case report
Publicado: (2021)

Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies
por: Patel, Jaydeep, et al.
Publicado: (2011)

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
por: El-Dahmy, Rania Moataz, et al.
Publicado: (2023)

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
por: Punzi, Henry A
Publicado: (2011)

Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil
por: Song, SaeHeum, et al.
Publicado: (2016)

Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation
por: Albash, Rofida, et al.
Publicado: (2019)

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
por: Chrysant, S G, et al.
Publicado: (2010)

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments
por: Almutairy, Bjad K., et al.
Publicado: (2021)

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2015)

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
por: Ferrario, Carlos
Publicado: (2009)

Simultaneous Estimation of Amlodipine Besilate and Olmesartan Medoxomil in Pharmaceutical Dosage Form
por: Wankhede, S. B., et al.
Publicado: (2009)

Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine
por: Ishizuka, Tomoko, et al.
Publicado: (2010)

Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability
por: Thadkala, Kiran, et al.
Publicado: (2014)

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis
por: Kumar, Lakshya, et al.
Publicado: (2023)

Enhancement of oral bioavailability of quercetin by metabolic inhibitory nanosuspensions compared to conventional nanosuspensions
por: Li, Haowen, et al.
Publicado: (2021)

Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
por: Arun, Jagdish Kumar, et al.
Publicado: (2020)

Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation
por: Nasr, Ali, et al.
Publicado: (2016)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
por: Mason, R Preston
Publicado: (2011)

Derivative and Q-analysis Spectrophotometric Methods for Estimation of Hydrochlorothiazide and Olmesartan Medoxomil in Tablets
por: Bhusari, K. P., et al.
Publicado: (2009)

Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization
por: Kanthamneni, Naveen, et al.
Publicado: (2016)

Development and validation of the simultaneous UV spectrophotometric method for estimation of metoprolol succinate and olmesartan medoxomil in the tablet dosage form
por: Vora, Bindi N., et al.
Publicado: (2012)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
por: Murillo-Fernández, Mac Arturo, et al.
Publicado: (2022)

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2016)

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
por: Barrios, Vivencio, et al.
Publicado: (2009)

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
por: Zhu, Ye, et al.
Publicado: (2019)

Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets
por: Darwish, Ibrahim A, et al.
Publicado: (2012)

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil
por: Hanumantha Rao, Bommena, et al.
Publicado: (2015)

Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment
por: Albash, Rofida, et al.
Publicado: (2019)

Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin
por: Li, Jun, et al.
Publicado: (2018)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8eoe8seso311b5ifv8nseokp37